| abstract |
This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. In particular, in vitro methods of predicting a human subject's likely response to treatment with olanzapine, risperidone, quetiapine, or perphenazine, or of selecting a treatment for schizophrenia comprising administration of olanzapine, risperidone, quetiapine, or perphenazine, comprising detecting a haplotype comprising one or more polymorphic markers in SLCO3A1 or markers in linkage disequilibrium (LD) therewith, are provided. |